Therefore, GLO1 is not only suitable as a predictive marker for tumor progression and therapeutic resistance, but also has potential clinical applications: by quantitatively detecting the expression level of GLO1 in cancer tissues or circulating tumor cells, the response or resistance risk of patients to conventional chemotherapeutic drugs can be assessed before clinical treatment, and then optimize personalized treatment plans. Here, GLO1 is linked to cancer.